Trial · NCT04303026
The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip
NCT04303026, Phase 3, Unknown, Vestre Viken Hospital Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip. Trials, record NCT04303026. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04303026
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip
- NCT number
- NCT04303026
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Vestre Viken Hospital Trust
- Conditions
- Osteoarthritis, Hip
- Interventions
- Zoledronic Acid, Saline 0.9%
- First posted
- 2020-03-10
- Last updated
- 2022-10-24
- Other registries' IDs
- eudract:2019-000757-31
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change in joint pain by VAS (Visual analogue pain scale from 1-10) from baseline to 12 months follow up, in the intervention group compared to the placebo group | Baseline and 12 months | Pain during weight bearing measured with Visual Analogue Pain Scale |
| Secondary | Mean change in joint pain by VAS from baseline to 3 and 6 months follow up, in the intervention group compared to the placebo group | baseline, 3 and 6 months | Pain during weight bearing measured with Visual Analogue Pain Scale |
| Secondary | Mean change in function and activity score (HOOS) from baseline to 3, 6 and 12 months follow up, in the intervention group compared to the placebo group | baseline, 3, 6 and 12 months | Function and activity measured with PROM (patient reported outcome measure) Hip Disability and Osteoarthritis, 0-100 worst to best scale |
| Secondary | Mean change in function and activity score (HHS) from baseline to 12 months follow up, in the intervention group compared to the placebo group | 12 months | Function and activity measured with Harris hips score, 0-100 worst to best score. |
| Secondary | Mean change in 40mWT (40 meter walking test measured in seconds) from baseline to 3, 6 and 12 months follow up, in intervention group compared to placebo group | baseline, 3, 6 and 12 months | 40 meter walking test measured in seconds |
| Secondary | Mean change in SCT (Stair climb test measured in seconds) from baseline to 3, 6 and 12 months follow up, in intervention group compared to placebo group | baseline, 3, 6 and 12 months | Stair Climb test measured in seconds (11 stairs) |
| Secondary | Mean change in 30CST (Chair stand test, measured by number of repetitions in 30 seconds) from baseline to 3, 6 and 12 months follow up, in intervention group compared to placebo group | baseline, 3, 6 and 12 months | Chair stand test measured in number of repetitions in 30 seconds |
| Secondary | Mean change in QoL (EQ-5D) from baseline to 3, 6 and 12 months follow up, in the intervention group compared to the placebo group | baseline, 3, 6 and 12 months | Use of Euroqol 5 questions (EQ-5D), measuring disease related quality of life. Score is calculated using value set from English population |
| Secondary | Change in mean number of doses of Paracetamol, NSAID and/or opiates per week in each group during the last month compared to baseline at 12 months follow up | baseline, 3, 6 and 12 months | Change in use of pain medication |
| Secondary | Number of AE/SAE (adverse events and serious adverse events) and AR/SAR/SUSAR (adverse/serious adverse and suspected unexpected serious adverse reactions) in the intervention group compared to placebo group 12 months after first infusion. | baseline and 12 months | Registrating number of adverse effects and adverse reactions |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers36
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04303026
GET https://conductscience.org/api/trials/v1/NCT04303026/papers?page=2